On the same note, nivolumab and pembrolizumab, both anti-PD-1 antibodies, demonstrated significantly different outcomes in clinical trials of non-small cell lung cancer (NSCLC) patients, which may be attributed to the differences in patient selection criteria based on PD-L1 expression levels (>5% or >50%).68 This evidence concerns the gene CD274 and non-small cell lung carcinoma.